Deferiprone chelation therapy for thalassemia major.

  title={Deferiprone chelation therapy for thalassemia major.},
  author={Renzo Galanello and Simona Campus},
  journal={Acta haematologica},
  volume={122 2-3},
Iron overload is one of the major causes of morbidity in patients with thalassemia major. Deferiprone (DFP), an orally active iron chelator, emerged from an extensive search for new drugs to treat iron overload. Comparative studies have shown that at comparable doses the efficacy of DFP in removing body iron is similar to that of desferoxamine (DFO). In retrospective and prospective studies, DFP monotherapy was significantly more effective than DFO in the treatment of myocardial siderosis in… CONTINUE READING